A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leukemia.

Publication Type:

Journal Article

Authors:

Byrd, John C; Pagel, John M; Awan, Farrukh T; Forero, Andres; Flinn, Ian W; Deauna-Limayo, Delva P; Spurgeon, Stephen E; Andritsos, Leslie A; Gopal, Ajay K; Leonard, John P; Eisenfeld, Amy J; Bannink, Jeannette E; Stromatt, Scott C; Furman, Richard R

Source:

Blood (2013)

Keywords:

2013, Clinical Research Division, January 2014

Abstract:

Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered intravenously to patients with chronic lymphocytic leukemia (CLL). Otlertuzumab was administered IV weekly for up to 8 weeks followed by 4 monthly doses ranging from 0.03 to 20 mg/kg in the dose escalation phase and 10 to 30 mg/kg in the expansion phase. Responses were determined using the 1996 NCI criteria and 2008 IWCLL criteria. Fifty-seven patients were treated in the dose-escalation phase and 26 in the expansion phase. A maximum tolerated dose (MTD) was not identified. Pharmacokinetics of otlertuzumab was dose-proportional with a median terminal half-life of 8 days. Response occurred in 19 of 83 treated patients (23%) by NCI-96 criteria. All responses were partial, and occurred more commonly in patients with symptomatic untreated CLL (6/7) or 1-2 prior therapies (12/28) versus 3 or more therapies (1/48). Twenty percent (12/61) with serial CT scan assessment had a response per IWCLL criteria. The most frequent adverse events were infusion reactions, fatigue, nausea, and diarrhea, and were not dose-related. Otlertuzumab was well tolerated and modest clinical activity was observed. Otlertuzumab warrants further evaluation in combination with other agents for the treatment of CLL.